UPDATE: Canaccord Lowers PT on AngioDynamics on Continued Tepid Business Trends

In a report published Friday, Canaccord Genuity reiterated its Hold rating on AngioDynamics

, but slightly lowered its price target from $12.50 to $11.50. Canaccord Genuity noted, “Coming out of ANGO's January analyst meeting, we expressed skepticism about growth prospects for the company's products – namely in Peripheral Vascular, Fluid Management and Access – given the sluggish growth dynamics in these markets. While some products (e.g. BioFlo) have more attractive growth prospects than others; overall we do not foresee consistent double-digit growth potential from existing businesses.” AngioDynamics closed on Thursday at $12.58.